Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment

Medicine and Dentistry

• Non Small Cell Lung Cancer 100%
• Epidermal Growth Factor Receptor 80%
• Chemotherapy 80%
• Anaplastic Lymphoma Kinase 80%
• Therapeutic Procedure 60%
• Patient 40%
• Microtubule Associated Protein 40%
• Biological Marker 20%
• Receptor Gene 20%
• Mutant 20%
• Progression Free Survival 20%
• Oncogene 20%
• Gefitinib 20%
• Epidermal Growth Factor Receptor Kinase Inhibitor 20%
• Erlotinib 20%
• Tyrosine-Kinase Inhibitor 20%
• Cyclic AMP Dependent Protein Kinase 20%
• Patient Selection 20%
• Treatment of Non-Small Cell Lung Cancer 20%
• Personalized Medicine 20%
• Crizotinib 20%

Biochemistry, Genetics and Molecular Biology

• Epidermal Growth Factor Receptor 100%
• Anaplastic Lymphoma Kinase 80%
• Mutation 60%
• Echinoderm 40%
• Microtubule-Associated Protein 40%
• Mutant 20%
• Receptor Gene 20%
• Genetics 20%
• Oncogene 20%
• Gefitinib 20%
• Receptor Tyrosine Kinase Inhibitors 20%
• Molecular Genetics 20%
• Progression Free Survival 20%
• Erlotinib 20%
• Crizotinib 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Epidermal Growth Factor Receptor 80%
• Anaplastic Lymphoma Kinase 80%
• Microtubule Associated Protein 40%
• Echinoderm 40%
• Biological Marker 20%
• Progression Free Survival 20%
• Epidermal Growth Factor Receptor Kinase Inhibitor 20%
• Gefitinib 20%
• Protein Tyrosine Kinase Inhibitor 20%
• Cyclic AMP Dependent Protein Kinase 20%
• Erlotinib 20%
• Crizotinib 20%